Issues related to lung disease and rare disease.
2026 · 1st Quarter (Jan 1 - Mar 31)
AVALYN PHARMA INC.
Filed by DLA PIPER LLP (US).
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 16, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- DLA PIPER LLP (US)
- Client
- AVALYN PHARMA INC.
- Filing UUID
- 2bf95d5f-9d5d-4413-b3cf-f7b1d1a3e4a2
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to lung disease and rare disease.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.